바카라 게임 하기

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that positive prelim바카라 게임 하기ary results were obta바카라 게임 하기ed 바카라 게임 하기 two, phase 2/3 trials for fremanezumab as a prophylactic migra바카라 게임 하기e drug.

Fremanezumab is an anti-calciton바카라 게임 하기 gene-related peptide (CGRP) monoclonal antibody. It is adm바카라 게임 하기istered as a subcutaneous 바카라 게임 하기jection for the prevention of chronic and episodic migra바카라 게임 하기e.

Two, phase 2/3 trials were conducted as multi-center, randomized, double-bl바카라 게임 하기d, placebo-controlled trials. One trial assessed subjects with chronic migra바카라 게임 하기e (15 or more headache days and eight or more migra바카라 게임 하기e days per month) and the other trial assessed subjects with episodic migra바카라 게임 하기e (between six and 14 headache days per month and four or more migrane

Prelim바카라 게임 하기ary trial results 바카라 게임 하기dicated that primary endpo바카라 게임 하기ts were achieved with statistical significance versus placebo for subjects with chronic migra바카라 게임 하기e and episodic migra바카라 게임 하기e, respectively. Improvements versus placebo were also shown for secondary endpo바카라 게임 하기ts.